Goodwin Biotechnology, Inc. has signed a development and manufacturing agreement with a multinational biopharmaceutical client, under which Goodwin will develop the process to manufacture a therapeutic monoclonal antibody conjugate for diagnostic imaging purposes. The product will be manufactured under cGMP conditions as a kit for radio-labeling for use in clinical trials. Terms of the agreement were not disclosed.

“This project will allow us to utilize our extensive experience and expertise in bio-conjugation technologies that we have honed over the last few years,” said Muctarr Sesay, Ph.D., vice president of process development at Goodwin Biotechnology. “We have had great history in developing and producing antibody-drug conjugates for diagnostic imaging and therapeutics, and this project is already underway with excellent progress.”